PROVEN SUPERIOR TO CLOPIDOGREL IN REDUCING CV DEATH AT 12 MONTHS
CV death secondary end point: RRR with BRILINTA plus aspirin was 21% (ARR 1.1%) vs clopidogrel plus aspirin.§1 INDICATIONS BRILINTA is indicated to reduce the rate of thrombotic CV events in patients with acute coronary syndrome (ACS) (unstable angina [UA], non–ST-elevation MI [NSTEMI], or ST-elevation MI [STEMI]). BRILINTA has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the ??????????????????? I%1%9Q???????????????????
L??????????????????????????5????????????????????????????????????????????????????????? I%1%9Q?????????????????????????????????????????????() 1%9 ?P???5=9Q!L??????????????????????????????????Q????5???? ?????????????????????????????1?????????????????????????? I%1%9Q?????????????????????????????????????????????????Q?????????????????????????9???M
???????5????????5???? ??????????? I%1%9Q????????????????????????????????????????????????????9???M
??????5???? ?????????????????????????????A1Q